La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Equasens Société anonyme Gestione
Gestione criteri di controllo 2/4
Equasens Société anonyme's Il CEO è Denis Supplisson, nominato in Apr2022, ha un mandato di 2.33 anni. possiede direttamente 0% delle azioni della società, per un valore di € 490.84. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 12.7 anni.
Informazioni chiave
Denis Supplisson
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 2.3yrs |
| Proprietà del CEO | 0.00007% |
| Durata media del management | 1.6yrs |
| Durata media del Consiglio di amministrazione | 12.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Equasens Société anonyme's (EPA:EQS) Intrinsic Value Is Potentially 75% Above Its Share Price
Jul 15
Equasens Société anonyme's (EPA:EQS) Upcoming Dividend Will Be Larger Than Last Year's
Jun 22Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Jun 07Equasens Société anonyme (EPA:EQS) Is Aiming To Keep Up Its Impressive Returns
Apr 03At €51.10, Is It Time To Put Equasens Société anonyme (EPA:EQS) On Your Watch List?
Mar 08Some Confidence Is Lacking In Equasens Société anonyme's (EPA:EQS) P/E
Feb 14Estimating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 27Should You Investigate Equasens Société anonyme (EPA:EQS) At €59.70?
Nov 29These 4 Measures Indicate That Equasens Société anonyme (EPA:EQS) Is Using Debt Safely
Oct 28A Look At The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Sep 27Should You Think About Buying Equasens Société anonyme (EPA:EQS) Now?
Aug 05Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.15
Jun 11Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 22Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 08What Does Equasens Société anonyme's (EPA:EQS) Share Price Indicate?
Apr 04Equasens Société anonyme (EPA:EQS) Will Want To Turn Around Its Return Trends
Feb 13Calculating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 26At €71.60, Is Equasens Société anonyme (EPA:EQS) Worth Looking At Closely?
Dec 21Should You Be Adding Equasens Société anonyme (EPA:EQS) To Your Watchlist Today?
Dec 07Here's What's Concerning About Equasens Société anonyme's (EPA:EQS) Returns On Capital
Nov 12Is Equasens Société anonyme (EPA:EQS) Trading At A 26% Discount?
Oct 27Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Oct 12When Should You Buy Equasens Société anonyme (EPA:EQS)?
Sep 09With EPS Growth And More, Equasens Société anonyme (EPA:EQS) Makes An Interesting Case
Aug 24Equasens Société anonyme (EPA:EQS) Might Be Having Difficulty Using Its Capital Effectively
Jul 28Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.05
Jun 10Pharmagest Interactive (EPA:PHA) Has Announced That It Will Be Increasing Its Dividend To €1.05
May 27Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
May 22Here's What Pharmagest Interactive's (EPA:PHA) Strong Returns On Capital Mean
Apr 25Are Investors Undervaluing Pharmagest Interactive SA (EPA:PHA) By 28%?
Feb 23Here's Why I Think Pharmagest Interactive (EPA:PHA) Might Deserve Your Attention Today
Feb 09Is Pharmagest Interactive SA (EPA:PHA) Potentially Undervalued?
Jan 25Many Would Be Envious Of Pharmagest Interactive's (EPA:PHA) Excellent Returns On Capital
Jan 06Pharmagest Interactive (EPA:PHA) Could Easily Take On More Debt
Nov 14Is There An Opportunity With Pharmagest Interactive SA's (EPA:PHA) 20% Undervaluation?
Oct 30Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
Sep 28Is Pharmagest Interactive SA (EPA:PHA) Trading At A 20% Discount?
Jul 18Pharmagest Interactive (EPA:PHA) Will Want To Turn Around Its Return Trends
Jun 24Does Pharmagest Interactive (EPA:PHA) Deserve A Spot On Your Watchlist?
Apr 08Pharmagest Interactive SA (EPA:PHA) Is An Attractive Dividend Stock - Here's Why
Mar 24Pharmagest Interactive SA's (EPA:PHA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 03Our Take On The Returns On Capital At Pharmagest Interactive (EPA:PHA)
Feb 09
Shareholders of Pharmagest Interactive (EPA:PHA) Must Be Delighted With Their 500% Total Return
Jan 12What To Know Before Buying Pharmagest Interactive SA (EPA:PHA) For Its Dividend
Dec 15Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmagest Interactive SA's EPA:PHA) Stock?
Dec 01Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | €47m |
| Jun 30 2023 | n/a | n/a | €48m |
| Mar 31 2023 | n/a | n/a | €47m |
| Dec 31 2022 | €400k | €176k | €46m |
| Jun 30 2022 | n/a | n/a | €42m |
| Mar 31 2022 | n/a | n/a | €41m |
| Dec 31 2021 | €353k | €133k | €39m |
| Sep 30 2021 | n/a | n/a | €37m |
| Jun 30 2021 | n/a | n/a | €35m |
| Mar 31 2021 | n/a | n/a | €33m |
| Dec 31 2020 | €371k | €133k | €31m |
| Sep 30 2020 | n/a | n/a | €29m |
| Jun 30 2020 | n/a | n/a | €27m |
| Mar 31 2020 | n/a | n/a | €27m |
| Dec 31 2019 | €225k | €133k | €27m |
| Sep 30 2019 | n/a | n/a | €27m |
| Jun 30 2019 | n/a | n/a | €26m |
| Mar 31 2019 | n/a | n/a | €26m |
| Dec 31 2018 | €208k | €128k | €25m |
| Sep 30 2018 | n/a | n/a | €25m |
| Jun 30 2018 | n/a | n/a | €24m |
| Mar 31 2018 | n/a | n/a | €24m |
| Dec 31 2017 | €189k | €114k | €23m |
Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Denis sia ragionevole rispetto ad aziende di dimensioni simili nel mercato French.
Compensazione vs guadagni: La retribuzione di Denis è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Denis Supplisson (55 yo)
2.3yrs
Mandato
€400,201
Compensazione
Mr. Denis Supplisson serves as Chief Executive Officer at Pharmagest Interactive SA since April 22, 2022. He served as Deputy Managing Director/Deputy Chief Executive Officer & Manager of the Europe Pharma...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder & Chairman of the Board | 14.6yrs | Nessun dato | 0.036% € 252.5k | |
| Deputy CEO | 4.1yrs | €428.66k | 0.000070% € 495.6 | |
| Chief Executive Officer & Director | 2.3yrs | €400.20k | 0.000070% € 495.6 | |
| Director | no data | €330.17k | 0.16% € 1.1m | |
| Group Chief Administrative & Financial Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Head of Communications | less than a year | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 4.8yrs | Nessun dato | Nessun dato | |
| Head of the Medical Solutions Division | less than a year | Nessun dato | Nessun dato | |
| Deputy MD & Head of the Pharmagest Division | less than a year | Nessun dato | Nessun dato |
1.6yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di EQS non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder & Chairman of the Board | 14.6yrs | Nessun dato | 0.036% € 252.5k | |
| Deputy CEO | 4.1yrs | €428.66k | 0.000070% € 495.6 | |
| Chief Executive Officer & Director | 11.6yrs | €400.20k | 0.000070% € 495.6 | |
| Director | 15.2yrs | €330.17k | 0.16% € 1.1m | |
| Director | 22.3yrs | €6.91k | 0.0033% € 23.6k | |
| Director | 13.6yrs | Nessun dato | Nessun dato | |
| Director | 13.6yrs | €7.07k | 0.0027% € 19.5k | |
| Director | 13.2yrs | Nessun dato | 0.0046% € 32.5k | |
| Independent Director | 12.2yrs | €6.76k | 0.00017% € 1.2k | |
| Independent Director | 7.2yrs | €6.91k | 0.00013% € 920.4 | |
| Director | 7.2yrs | €604.00 | 0.00011% € 778.8 | |
| Independent Director | 1.2yrs | Nessun dato | 0.000010% € 70.8 |
12.7yrs
Durata media
57.5yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di EQS è composto da personale esperto e esperto (durata media dell'incarico 12.7 anni).